Analyst: Insulet On Track For Profitability In 2018


27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


Insulet Corporation (NASDAQ:PODD) is up 80.5 percent year-over-year, and even last quarter’s bottom-line miss can’t deter the biotech’s bulls.

The Rating

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

BMO Capital Markets analyst Joanne Wuensch initiated coverage of Insulet Corp. with an Outperform rating and $90 price target.

The Thesis

Wuensch anticipates a turn to profitability in the second half of 2018, with a series of catalysts sustaining positive performance.

Over the next two years, Insulet is expected to profit from the rollout of the OmniPod Dash platform and Horizon Automated Glucose Control System; a push for international direct sales; penetration of the U.S. Medicare market; approved distribution of higher concentration insulin; and expansion in Type 2 diabetes, the analyst said. 


Want Private Access to Benzinga Analyst?

Check out the latest strategies our team of experts are using every week so that you can always adapt to the market like the pros!—Get FULL Access to This Week's Webinar Here.


At the same time, its Omnipod product is positioned to expand in an “underpenetrated” insulin pump market and capture the share abandoned by Roche and Johnson & Johnson (NYSE:JNJ), Wuensch said. The analyst said she expects a three-year share expansion from 15.2 percent to 22.1 percent.

“Insulet is on the right side of care with its OmniPod Pump, providing an easier, more efficacious means of insulin delivery without the obstacles of traditional pumps or multiple daily injections,” she said in a Monday note. 

Price Action

Insulet shares were up 2.31 percent at $77.57 in midday trading Tuesday. 

Related Links:

7 Biotech Stocks With Clinical Trial Outcomes In March

Pharma M&A Picks Up Momentum


27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


Posted In: Analyst ColorBiotechPrice TargetInitiationAnalyst RatingsGeneralBMO Capital MarketsJoanne Wuensch